ZA9510806B - Anti-xv-integrin monoclonal antibody - Google Patents

Anti-xv-integrin monoclonal antibody

Info

Publication number
ZA9510806B
ZA9510806B ZA9510806A ZA9510806A ZA9510806B ZA 9510806 B ZA9510806 B ZA 9510806B ZA 9510806 A ZA9510806 A ZA 9510806A ZA 9510806 A ZA9510806 A ZA 9510806A ZA 9510806 B ZA9510806 B ZA 9510806B
Authority
ZA
South Africa
Prior art keywords
monoclonal antibody
integrin monoclonal
integrin
antibody
monoclonal
Prior art date
Application number
ZA9510806A
Other languages
English (en)
Inventor
Francesc Mitjans
Elisabet Rosell
Simon Goodmann
Jaime Piulats
Jaume Adan
Diane Hahn
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA9510806(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA9510806B publication Critical patent/ZA9510806B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA9510806A 1994-12-20 1995-12-19 Anti-xv-integrin monoclonal antibody ZA9510806B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94120165 1994-12-20

Publications (1)

Publication Number Publication Date
ZA9510806B true ZA9510806B (en) 1996-05-30

Family

ID=8216547

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9510806A ZA9510806B (en) 1994-12-20 1995-12-19 Anti-xv-integrin monoclonal antibody

Country Status (26)

Country Link
US (1) US5985278A (sv)
EP (1) EP0719859B1 (sv)
JP (1) JP3898245B2 (sv)
KR (1) KR100450368B1 (sv)
CN (1) CN1117763C (sv)
AR (1) AR001778A1 (sv)
AT (1) ATE244306T1 (sv)
AU (1) AU710234B2 (sv)
BR (1) BR9505980B1 (sv)
CA (1) CA2165573C (sv)
CO (1) CO4480042A1 (sv)
CZ (1) CZ290477B6 (sv)
DE (1) DE69531187T2 (sv)
DK (1) DK0719859T3 (sv)
ES (1) ES2202336T3 (sv)
FI (1) FI118536B (sv)
HU (1) HU221061B1 (sv)
NO (1) NO321186B1 (sv)
PL (1) PL182961B1 (sv)
PT (1) PT719859E (sv)
RU (1) RU2205223C2 (sv)
SI (1) SI0719859T1 (sv)
SK (1) SK284932B6 (sv)
TR (1) TR199501614A2 (sv)
UA (1) UA40621C2 (sv)
ZA (1) ZA9510806B (sv)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4134497A (en) * 1996-09-03 1998-03-26 Chugai Seiyaku Kabushiki Kaisha Anti-integrin alpha3 antibody complexes
ES2321991T3 (es) * 1996-12-09 2009-06-15 Merck Patent Gmbh Receptor de adhesion alfavbet3 recombinante soluble.
EE04752B1 (et) * 1997-08-08 2006-12-15 The Regents Of The University Of California Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine
AU2716399A (en) * 1998-01-23 1999-08-09 Merck Patent Gmbh Monoclonal antibody anti alphav-integrin and its use to inhibit alphavbeta6-integrin attachment to fibronectin
US6160099A (en) 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US7153944B2 (en) * 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7064180B2 (en) 2000-07-31 2006-06-20 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7323552B2 (en) * 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US20020168360A1 (en) * 2001-03-02 2002-11-14 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphanubeta3 antagonists in combination with other prophylactic or therapeutic agents
WO2002085405A2 (en) 2001-04-24 2002-10-31 Merck Patent Gmbh COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
WO2003006893A2 (en) * 2001-07-09 2003-01-23 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
CA2478239A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
AU2003213682C1 (en) * 2002-03-04 2008-06-12 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin alphavbeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
CN102924598B (zh) * 2002-03-13 2014-12-31 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
CN100509851C (zh) * 2002-03-13 2009-07-08 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
EP2270049A3 (en) 2002-04-12 2011-03-09 Medimmune, Inc. Recombinant anti-interleukin-9-antibody
CA2481922A1 (en) * 2002-04-12 2003-10-23 Raven Biotechnologies, Inc. Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
US20040176272A1 (en) * 2003-01-30 2004-09-09 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
WO2004091510A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
WO2008060645A2 (en) 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy involving alpha5beta1 antagonists
CN101563105B (zh) 2006-07-10 2013-01-23 拜奥根Idec马萨诸塞公司 用于抑制smad4-缺陷癌症的组合物和方法
EP2043603A4 (en) 2006-07-11 2010-10-27 Arubor Corp PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS
HUE048024T2 (hu) 2006-08-10 2020-05-28 Roy C Levitt Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra
US20090175784A1 (en) 2007-05-11 2009-07-09 Joshua Goldstein Anti-Alpha V Immunoliposome Composition, Methods, and Uses
US20090196913A1 (en) * 2007-05-11 2009-08-06 Ken Shi Kun Huang Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
BRPI0815567B8 (pt) * 2007-07-17 2021-05-25 Merck Patent Gessellschaft Mit Beschraenkter Haftung anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica
AR066170A1 (es) 2007-09-26 2009-07-29 Genentech Inc Anti integrina alfa 5 beta 1
EP2706358A3 (en) 2008-12-23 2014-05-07 Merck Patent GmbH Biomarkers for inhibitors with anti-angiogenic activity
CA2753988C (en) 2009-03-25 2017-04-25 Genentech, Inc. Novel anti-.alpha.5.beta. integrin antibodies and uses thereof
CA2780773A1 (en) 2009-11-13 2011-05-19 Merck Patent Gmbh Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
CA2790488C (en) * 2010-02-18 2018-09-25 The Regents Of The University Of California Integrin .alpha.v.beta.8 neutrilizing antibody
WO2012027745A1 (en) * 2010-08-27 2012-03-01 University Of Miami Treatment of renal diseases
EP3415162A1 (en) 2011-02-11 2018-12-19 Merck Patent GmbH Anti-alpha-v integrin antibody for the treatment of prostate cancer
CN103826661B (zh) 2011-04-21 2019-03-05 西雅图基因公司 新的结合剂-药物缀合物(adc)及其用途
WO2013026004A2 (en) * 2011-08-17 2013-02-21 The Regents Of The University Of California Antibodies that bind integrin alpha-v beta-8
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
NZ720736A (en) 2013-12-23 2020-08-28 Bayer Pharma AG Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
SG11201702135PA (en) 2014-09-17 2017-04-27 Merck Patent Gmbh A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
MX2017003406A (es) 2014-09-17 2017-06-19 Merck Patent Gmbh Metodo para tratar enfermedades de metastasis osea, medicamentos para las mismas, y metodo para predecir el resultado clinico para tratar enfermedades de metastasis osea.
CA2990076A1 (en) 2015-06-22 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
PE20180452A1 (es) 2015-06-23 2018-03-05 Bayer Pharma AG Conjugados homogeneos especificos de sitio con inhibidores de ksp
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US20190144547A1 (en) 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
MX2018011627A (es) 2016-03-24 2019-01-10 Bayer Pharma AG Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles.
EP3471776B1 (en) 2016-06-15 2022-05-04 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies
JP2019533139A (ja) 2016-09-08 2019-11-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ネフローゼ症候群を診断及び処置するための方法
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
AU2017380871A1 (en) 2016-12-21 2019-07-11 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
KR101961715B1 (ko) 2018-07-18 2019-03-25 (주) 삼진정밀 고효율 수처리장치
WO2020079209A1 (en) 2018-10-19 2020-04-23 Merck Patent Gmbh Abituzumab for the treatment of colorectal cancer
KR101999620B1 (ko) 2019-03-26 2019-07-12 조용진 부상슬러지 및 침전슬러지의 동시처리장치
BR112021020116A2 (pt) * 2019-04-08 2021-12-07 Biogen Ma Inc Anticorpos anti-integrina e usos dos mesmos
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0633945B1 (en) * 1992-04-03 1998-12-30 Genentech, Inc. ANTIBODIES TO ALPHAvBETA3 INTEGRIN
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis

Also Published As

Publication number Publication date
DK0719859T3 (da) 2003-10-20
BR9505980B1 (pt) 2010-02-23
NO955167L (no) 1996-06-21
JPH08231597A (ja) 1996-09-10
US5985278A (en) 1999-11-16
KR960022562A (ko) 1996-07-18
ES2202336T3 (es) 2004-04-01
TR199501614A2 (tr) 1996-07-21
BR9505980A (pt) 1997-12-23
EP0719859B1 (en) 2003-07-02
CZ290477B6 (cs) 2002-07-17
RU2205223C2 (ru) 2003-05-27
HU9503638D0 (en) 1996-02-28
EP0719859A1 (en) 1996-07-03
DE69531187D1 (de) 2003-08-07
UA40621C2 (uk) 2001-08-15
HUT74828A (en) 1997-02-28
SK284932B6 (sk) 2006-02-02
JP3898245B2 (ja) 2007-03-28
FI956112A0 (sv) 1995-12-19
PL182961B1 (pl) 2002-05-31
ATE244306T1 (de) 2003-07-15
CN1117763C (zh) 2003-08-13
CA2165573A1 (en) 1996-06-21
SI0719859T1 (en) 2003-12-31
CA2165573C (en) 2011-03-29
PT719859E (pt) 2003-11-28
AR001778A1 (es) 1997-12-10
FI118536B (sv) 2007-12-14
CZ328895A3 (en) 1996-09-11
SK159295A3 (en) 1996-07-03
KR100450368B1 (ko) 2005-01-31
NO321186B1 (no) 2006-04-03
PL311926A1 (en) 1996-06-24
FI956112A (sv) 1996-06-21
NO955167D0 (no) 1995-12-19
HU221061B1 (hu) 2002-07-29
DE69531187T2 (de) 2004-04-22
AU4042195A (en) 1996-06-27
CN1139115A (zh) 1997-01-01
CO4480042A1 (es) 1997-07-09
AU710234B2 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
ZA9510806B (en) Anti-xv-integrin monoclonal antibody
IL128406A0 (en) Monoclonal antibodies
ZA959336B (en) Antibodies
GB9603256D0 (en) Antibodies
GB9412166D0 (en) Retargetting antibodies
EP0580859A4 (en) Anti-eda monoclonal antibody
GB9608626D0 (en) Hepatitis b monoclonal antibodies
EP0977590A4 (en) HUMAN MONOCLONAL ANTIBODIES
EP0909278A4 (en) IMMUNOGLOBULIN G LINKED TO NEPHROPATHY AND ANTIBODIES AGAINST IT
EP0506523A3 (en) Monoclonal antibodies
ZA951113B (en) Tumor assosiated monoclonal antibody 123av16
GB9718911D0 (en) Monoclonal antibodies
HUP9901579A3 (en) Antibodies specific for alpha-d-integrin
EP0654532A4 (en) ANTIMUCOGLYCOPROTEIN MONOCLONAL ANTIBODIES.
ZA912136B (en) Anti-oncostatin m monoclonal antibodies
GB9615027D0 (en) Monoclonal antibodies
AP9801381A0 (en) Anti-human mp52 monoclonal antibody
ZA954678B (en) Monoclonal antibody against cd44v6
SI0742795T1 (en) Immuno-stimulatory monoclonal antibodies
GB9212074D0 (en) Monoclonal antibody
SG64332A1 (en) Monoclonal antibody
GB9512314D0 (en) Antibody
GB9406222D0 (en) Huminised antibodies
GB9415331D0 (en) Antibodies
IL134049A0 (en) Anti-cryptdin antibodies